We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+13.53%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$652M
AUM Growth
+$113M
Cap. Flow
+$93.9M
Cap. Flow %
14.4%
Top 10 Hldgs %
48.49%
Holding
247
New
47
Increased
63
Reduced
54
Closed
37

Top Buys

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$52.7M
2
PRTA icon
Prothena Corp
PRTA
+$25.3M
3
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$13M
4
CYTK icon
Cytokinetics
CYTK
+$6.66M
5
SVRA icon
Savara
SVRA
+$6.09M

Top Sells

Rank Stock Value
1
ROIV icon
Roivant Sciences
ROIV
+$16.7M
2
SWTX
SpringWorks Therapeutics
SWTX
+$8.17M
3
IMVT icon
Immunovant
IMVT
+$6.56M
4
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$6.34M
5
AVR
Anteris Technologies
AVR
+$4.66M

Sector Composition

Rank Sector Weight
1 Healthcare 78.96%
2 Financials 2.75%
3 Consumer Staples 0.04%
4 Technology 0%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XNCR icon
101
Xencor
XNCR
$1.48B
$675K 0.1%
85,826
-312,326
-78% -$2.8M
CTNM
102
Contineum Therapeutics
CTNM
$584M
$662K 0.1%
166,799
-1,966
-1% -$8.54K
BIIB icon
103
Biogen
BIIB
$30.9B
$641K 0.1%
5,100
+600
+13% +$74.8K
GERN icon
104
Geron
GERN
$1.01B
$622K 0.1%
441,176
+175,000
+66% +$248K
PHAT icon
105
Phathom Pharmaceuticals
PHAT
$693M
$608K 0.09%
63,424
+20,624
+48% +$114K
PHVS icon
106
Pharvaris
PHVS
$2.31B
$601K 0.09%
+34,124
New +$550K
LXEO icon
107
Lexeo Therapeutics
LXEO
$350M
$583K 0.09%
145,109
-25,339
-15% -$83.3K
KYMR icon
108
Kymera Therapeutics
KYMR
$8.76B
$583K 0.09%
13,366
+3,366
+34% +$116K
OABI icon
109
OmniAb
OABI
$302M
$567K 0.09%
326,108
+200,000
+159% +$335K
MRK icon
110
Merck
MRK
$322B
$557K 0.09%
+7,040
New +$560K
LUNG icon
111
Pulmonx
LUNG
$80.7M
$530K 0.08%
+204,497
New +$807K
GRCE
112
Grace Therapeutics
GRCE
$34.2M
$525K 0.08%
176,627
-166,885
-49% -$444K
EWTX icon
113
Edgewise Therapeutics
EWTX
$4.84B
$524K 0.08%
40,000
+20,000
+100% +$288K
AVTX icon
114
Avalo Therapeutics
AVTX
$991M
$523K 0.08%
104,730
+94,730
+947% +$442K
SYRE icon
115
Spyre Therapeutics
SYRE
$8.96B
$510K 0.08%
34,051
+19,018
+127% +$281K
USFR icon
116
WisdomTree Floating Rate Treasury Fund
USFR
$18.4B
$503K 0.08%
10,000
– –
DNLI icon
117
Denali Therapeutics
DNLI
$3.85B
$500K 0.08%
35,716
+21,843
+157% +$307K
SNY icon
118
Sanofi
SNY
$103B
$483K 0.07%
+10,000
New +$511K
KPRX icon
119
Kiora Pharmaceuticals
KPRX
$11M
$481K 0.07%
167,111
-27,554
-14% -$84K
BHVN icon
120
Biohaven
BHVN
$2.05B
$456K 0.07%
32,341
+9,700
+43% +$173K
NGNE icon
121
Neurogene
NGNE
$704M
$443K 0.07%
29,625
+1,700
+6% +$26.7K
NETD
122
DELISTED
Nabors Energy Transition Corp II
NETD
$443K 0.07%
39,900
– –
NTRA icon
123
Natera
NTRA
$39.7B
$422K 0.06%
2,500
-1,750
-41% -$273K
SPRO icon
124
Spero Therapeutics
SPRO
$72.4M
$417K 0.06%
143,917
-657,360
-82% -$946K
NKTR icon
125
Nektar Therapeutics
NKTR
$2.48B
$408K 0.06%
15,796
+11,279
+250% +$127K
3 4
5
6 7

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return

ADAR1 Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, ADAR1 Capital Management held 247 positions worth $652M, up 21% from $539M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

ADAR1 Capital Management deployed $93.9M of net new capital in Q2 2025, opening 47 new positions and adding to 63 existing holdings. Its largest new stake was Prothena Corp: 3,375,009 shares worth $20.5M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 78% a quarter earlier, followed by Financials and Consumer Staples.

On the sell side, the largest reduction was Roivant Sciences, an estimated $16.7M trimmed.

  • ADAR1 Capital Management's largest Q2 2025 buy was Prothena Corp: 3,375,009 shares worth $20.5M.
  • ADAR1 Capital Management added most to Keros Therapeutics in Q2 2025, an estimated $52.7M increase.
  • ADAR1 Capital Management's biggest Q2 2025 reduction was Roivant Sciences, cutting an estimated $16.7M.
  • ADAR1 Capital Management fully exited Intra-Cellular Therapies Inc. in Q2 2025, selling an estimated $6.34M.
  • ADAR1 Capital Management's ten largest holdings make up 48% of its $652M portfolio in Q2 2025.
  • ADAR1 Capital Management opened 47 new positions and closed 37 in Q2 2025.
  • ADAR1 Capital Management's portfolio value rose 21% quarter-over-quarter to $652M.

Based on ADAR1 Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.